Table 3.
Risk of death from all causes in the entire IP cohort and in the RA subgroup, by clinical characteristics and HLA–DRB1 and PTPN22 genotypes*
| Entire IP cohort (n = 1,022) |
RA subgroup (met ACR criteria by the tenth year) (n = 751) |
|||
|---|---|---|---|---|
| Group | No. of patients | HR (95% CI) | No. of patients | HR (95% CI) |
| CRP at baseline | ||||
| ≤10 mg/dl (comparator) | 580 | 1.00 | 382 | 1.00 |
| >10 mg/dl | 278 | 1.56 (1.19–2.06) | 242 | 1.66 (1.22–2.26) |
| Smoking status at baseline | ||||
| Never smoked (comparator) | 314 | 1.00 | 240 | 1.00 |
| Ex-smoker | 424 | 1.02 (0.73–1.43) | 309 | 1.07 (0.73–1.56) |
| Current smoker | 268 | 1.43 (0.97–2.11) | 192 | 1.54 (1.00–2.38) |
| Never smoked or ex-smoker at baseline (comparator) | 738 | 1.00 | 549 | 1.00 |
| First tertile of smoking duration at baseline (0–25 years) | 95 | 1.41 (0.50–3.96) | 61 | 1.45 (0.45–4.71) |
| Second tertile of smoking duration at baseline (26–39 years) | 84 | 1.53 (0.80–2.93) | 59 | 1.43 (0.64–3.19) |
| Third tertile of smoking duration at baseline (40–68 years) | 87 | 1.39 (0.99–1.94) | 70 | 1.49 (1.03–2.15) |
| RF titer at baseline | ||||
| <1:40 (comparator) | 671 | 1.00 | 445 | 1.00 |
| ≥1:40 | 275 | 1.61 (1.24–2.1) | 247 | 1.74 (1.30–2.34) |
| Anti-CCP antibodies at baseline | ||||
| No (comparator) | 536 | 1.00 | 335 | 1.00 |
| Yes | 204 | 1.37 (1.00–1.88) | 186 | 1.50 (1.04–2.15) |
| SE alleles | ||||
| 0 copies of SE alleles (comparator) | 416 | 1.00 | 288 | 1.00 |
| 1 copy of SE alleles | 460 | 0.98 (0.74–1.30) | 349 | 0.96 (0.70–1.32) |
| 2 copies of SE alleles | 146 | 1.55 (1.08–2.24) | 114 | 1.54 (1.03–2.31) |
| 0 or 1 SE allele (comparator) | 876 | 1.00 | 637 | 1.00 |
| 2 SE alleles | 146 | 1.57 (1.13–2.19) | 114 | 1.58 (1.10–2.27) |
| 0 or 1 SE allele (comparator) | 876 | 1.00 | 637 | 1.00 |
| HLA–DRB1*01/*01 | 15 | 1.89 (0.70–5.11) | 11 | 1.74 (0.55–5.48) |
| HLA–DRB1*01/*04 | 59 | 1.99 (1.24–3.19) | 43 | 2.25 (1.34–3.79) |
| HLA–DRB1*0101/*0401 | 36 | 1.66 (0.94–2.92) | 24 | 1.72 (0.90–3.27) |
| HLA–DRB1*0101/*0404 | 12 | 3.00 (0.94–9.52) | 10 | 3.30 (1.03–10.57) |
| HLA–DRB1*04/*04 | 63 | 1.26 (0.75–2.09) | 52 | 1.15 (0.65–2.03) |
| HLA–DRB1*0401/*0401 | 16 | 2.63 (1.22–5.64) | 14 | 2.38 (1.04–5.45) |
| HLA–DRB1*0401/*0404 | 33 | 0.96 (0.47–1.96) | 26 | 0.83 (0.36–1.88) |
| PTPN22*1858T allele | ||||
| Negative (comparator) | 608 | 1.00 | 435 | 1.00 |
| Positive | 181 | 1.07 (0.73–1.55) | 126 | 0.76 (0.47–1.21) |
*
Data were adjusted for age at symptom onset and sex. IP = inflammatory polyarthritis; RA = rheumatoid arthritis; ACR = American College of Rheumatology; HR = hazard ratio; 95% CI = 95% confidence interval; CRP = C-reactive protein; RF = rheumatoid factor; anti-CCP = anti–cyclic citrullinated peptide; SE = shared epitope.